Advertisement
UK markets closed
  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     
  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     
  • AIM

    755.28
    +2.16 (+0.29%)
     
  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     
  • GBP/USD

    1.2494
    -0.0017 (-0.13%)
     
  • Bitcoin GBP

    51,072.85
    -649.00 (-1.25%)
     
  • CMC Crypto 200

    1,328.20
    -68.33 (-4.89%)
     
  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     
  • DOW

    38,239.66
    +153.86 (+0.40%)
     
  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     
  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     
  • DAX

    18,161.01
    +243.73 (+1.36%)
     
  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

Monthly information related to total number of voting rights and shares composing the share capital - March 31, 2019

LYON, France, April 02, 2019 (GLOBE NEWSWIRE) --

Article 223-16 of general regulation of French Autorité des Marchés Financiers
Lyon - France

Listing markets:
Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (ERYP.PA)
Website : www.erytech.com

Date

Total of shares composing the share capital

Total of brut(1) voting rights



Total of net(2) voting rights

December 31, 2018

17 940 035

19 525 606

19 523 106

January 31, 2019

17 940 035

19 525 918

19 523 418

February 28, 2019

17 940 035

19 525 792

19 523 292

March 31, 2019

17 940 035

19 525 808

19 523 308

(1)

Gross voting rights number (or « theoretical » voting rights) is used as a basis for calculating the crossing of the threshold. In accordance with article 223-11 of general regulation of Autorité des Marchés Financiers, this number is calculated on the basis of all shares carrying the single and double voting rights, including shares without voting rights.

(2)

Without treasury shares.

Press Release



This announcement is distributed by West Corporation on behalf of West Corporation clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Erytech Pharma S.A. via GlobeNewswire

HUG#2240505